Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients
Identifieur interne : 000006 ( PascalFrancis/Checkpoint ); précédent : 000005; suivant : 000007Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients
Auteurs : Santiago Perez-Lloret [France] ; María Ver Nica Rey [France] ; James Crispo [Canada] ; Daniel Krewski [Canada] ; Marise Lapeyre-Mestre [France] ; Jean-Louis Montastruc [France] ; Olivier Rascol [France]Source :
- Expert opinion on drug safety [ 1474-0338 ] ; 2014.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme, Médicament.
English descriptors
- KwdEn :
Abstract
Introduction: Dopamine agonists (DAs) are frequently used to treat early or advanced Parkinson's disease (PD) patients. They have been shown to be efficacious for the treatment of motor symptoms and for delaying levodopa-induced dyskinesias. However, their utilization is limited by the risk of adverse drug reactions, some of which affect the cardiovascular system. Recently, the US FDA identified a possible association between exposure to pramipexole and the risk of heart failure. Areas covered: This article begins by reviewing the pharmacodynamic and cardiovascular effects of DAs on PD patients. Pharmacoepidemiological studies about the association between DAs and heart failure are then evaluated. Expert opinion: Four nested case-control studies were reviewed. In general, results showed higher heart failure risk following use of pramipexole or cabergoline. Although the effects of cabergoline may be explained by the induction of cardiac valve fibrosis, the basis for the significantly increased risk associated with pramipexole is unclear. It remains to be determined if these are dose-related effects, at what point they occur during the course of treatment, and if the risk is the same for all patients irrespective of other potential modifying factors, such as age and sex.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:14-0095204Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients</title><author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Rey, Maria Ver Nica" sort="Rey, Maria Ver Nica" uniqKey="Rey M" first="María Ver Nica" last="Rey">María Ver Nica Rey</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Crispo, James" sort="Crispo, James" uniqKey="Crispo J" first="James" last="Crispo">James Crispo</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Ottawa, McLaughlin Centre for Population Health Risk Assessment, 1 Stewart Street</s1><s2>Ottawa, Ontario, K1N 6N5</s2><s3>CAN</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ottawa, Ontario, K1N 6N5</wicri:noRegion></affiliation></author><author><name sortKey="Krewski, Daniel" sort="Krewski, Daniel" uniqKey="Krewski D" first="Daniel" last="Krewski">Daniel Krewski</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Ottawa, McLaughlin Centre for Population Health Risk Assessment, 1 Stewart Street</s1><s2>Ottawa, Ontario, K1N 6N5</s2><s3>CAN</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ottawa, Ontario, K1N 6N5</wicri:noRegion></affiliation></author><author><name sortKey="Lapeyre Mestre, Marise" sort="Lapeyre Mestre, Marise" uniqKey="Lapeyre Mestre M" first="Marise" last="Lapeyre-Mestre">Marise Lapeyre-Mestre</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Faculty of Medicine, Department of Clinical Pharmacology, 37 Allées Jules Guesde</s1><s2>31000, Toulouse</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">14-0095204</idno><date when="2014">2014</date><idno type="stanalyst">PASCAL 14-0095204 INIST</idno><idno type="RBID">Pascal:14-0095204</idno><idno type="wicri:Area/PascalFrancis/Corpus">000031</idno><idno type="wicri:Area/PascalFrancis/Curation">000B87</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000006</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000006</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients</title><author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Rey, Maria Ver Nica" sort="Rey, Maria Ver Nica" uniqKey="Rey M" first="María Ver Nica" last="Rey">María Ver Nica Rey</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Crispo, James" sort="Crispo, James" uniqKey="Crispo J" first="James" last="Crispo">James Crispo</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Ottawa, McLaughlin Centre for Population Health Risk Assessment, 1 Stewart Street</s1><s2>Ottawa, Ontario, K1N 6N5</s2><s3>CAN</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ottawa, Ontario, K1N 6N5</wicri:noRegion></affiliation></author><author><name sortKey="Krewski, Daniel" sort="Krewski, Daniel" uniqKey="Krewski D" first="Daniel" last="Krewski">Daniel Krewski</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Ottawa, McLaughlin Centre for Population Health Risk Assessment, 1 Stewart Street</s1><s2>Ottawa, Ontario, K1N 6N5</s2><s3>CAN</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ottawa, Ontario, K1N 6N5</wicri:noRegion></affiliation></author><author><name sortKey="Lapeyre Mestre, Marise" sort="Lapeyre Mestre, Marise" uniqKey="Lapeyre Mestre M" first="Marise" last="Lapeyre-Mestre">Marise Lapeyre-Mestre</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Faculty of Medicine, Department of Clinical Pharmacology, 37 Allées Jules Guesde</s1><s2>31000, Toulouse</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author></analytic><series><title level="j" type="main">Expert opinion on drug safety</title><title level="j" type="abbreviated">Expert opin. drug saf.</title><idno type="ISSN">1474-0338</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Expert opinion on drug safety</title><title level="j" type="abbreviated">Expert opin. drug saf.</title><idno type="ISSN">1474-0338</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term><term>Bibliographic review</term><term>Cardiovascular disease</term><term>Dopamine agonist</term><term>Drug</term><term>Heart failure</term><term>Human</term><term>Neuroprotective agent</term><term>Parkinson disease</term><term>Pharmacovigilance</term><term>Pramipexole</term><term>Review</term><term>Risk factor</term><term>Toxicity</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Facteur risque</term><term>Insuffisance cardiaque</term><term>Traitement</term><term>Stimulant dopaminergique</term><term>Maladie de Parkinson</term><term>Homme</term><term>Toxicité</term><term>Médicament</term><term>Pathologie de l'appareil circulatoire</term><term>Pharmacovigilance</term><term>Pramipexole</term><term>Article synthèse</term><term>Revue bibliographique</term><term>Antiparkinsonien</term><term>Neuroprotecteur</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term><term>Médicament</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Introduction: Dopamine agonists (DAs) are frequently used to treat early or advanced Parkinson's disease (PD) patients. They have been shown to be efficacious for the treatment of motor symptoms and for delaying levodopa-induced dyskinesias. However, their utilization is limited by the risk of adverse drug reactions, some of which affect the cardiovascular system. Recently, the US FDA identified a possible association between exposure to pramipexole and the risk of heart failure. Areas covered: This article begins by reviewing the pharmacodynamic and cardiovascular effects of DAs on PD patients. Pharmacoepidemiological studies about the association between DAs and heart failure are then evaluated. Expert opinion: Four nested case-control studies were reviewed. In general, results showed higher heart failure risk following use of pramipexole or cabergoline. Although the effects of cabergoline may be explained by the induction of cardiac valve fibrosis, the basis for the significantly increased risk associated with pramipexole is unclear. It remains to be determined if these are dose-related effects, at what point they occur during the course of treatment, and if the risk is the same for all patients irrespective of other potential modifying factors, such as age and sex.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1474-0338</s0></fA01><fA03 i2="1"><s0>Expert opin. drug saf.</s0></fA03><fA05><s2>13</s2></fA05><fA06><s2>3</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients</s1></fA08><fA11 i1="01" i2="1"><s1>PEREZ-LLORET (Santiago)</s1></fA11><fA11 i1="02" i2="1"><s1>REY (María Verónica)</s1></fA11><fA11 i1="03" i2="1"><s1>CRISPO (James)</s1></fA11><fA11 i1="04" i2="1"><s1>KREWSKI (Daniel)</s1></fA11><fA11 i1="05" i2="1"><s1>LAPEYRE-MESTRE (Marise)</s1></fA11><fA11 i1="06" i2="1"><s1>MONTASTRUC (Jean-Louis)</s1></fA11><fA11 i1="07" i2="1"><s1>RASCOL (Olivier)</s1></fA11><fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></fA14><fA14 i1="02"><s1>University of Ottawa, McLaughlin Centre for Population Health Risk Assessment, 1 Stewart Street</s1><s2>Ottawa, Ontario, K1N 6N5</s2><s3>CAN</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ></fA14><fA14 i1="03"><s1>Faculty of Medicine, Department of Clinical Pharmacology, 37 Allées Jules Guesde</s1><s2>31000, Toulouse</s2><s3>FRA</s3><sZ>7 aut.</sZ></fA14><fA20><s1>351-360</s1></fA20><fA21><s1>2014</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>28166</s2><s5>354000501182730090</s5></fA43><fA44><s0>0000</s0><s1>© 2014 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>61 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>14-0095204</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Expert opinion on drug safety</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>Introduction: Dopamine agonists (DAs) are frequently used to treat early or advanced Parkinson's disease (PD) patients. They have been shown to be efficacious for the treatment of motor symptoms and for delaying levodopa-induced dyskinesias. However, their utilization is limited by the risk of adverse drug reactions, some of which affect the cardiovascular system. Recently, the US FDA identified a possible association between exposure to pramipexole and the risk of heart failure. Areas covered: This article begins by reviewing the pharmacodynamic and cardiovascular effects of DAs on PD patients. Pharmacoepidemiological studies about the association between DAs and heart failure are then evaluated. Expert opinion: Four nested case-control studies were reviewed. In general, results showed higher heart failure risk following use of pramipexole or cabergoline. Although the effects of cabergoline may be explained by the induction of cardiac valve fibrosis, the basis for the significantly increased risk associated with pramipexole is unclear. It remains to be determined if these are dose-related effects, at what point they occur during the course of treatment, and if the risk is the same for all patients irrespective of other potential modifying factors, such as age and sex.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02U</s0></fC02><fC02 i1="02" i2="X"><s0>002B12A01</s0></fC02><fC02 i1="03" i2="X"><s0>002B17G</s0></fC02><fC02 i1="04" i2="X"><s0>002B17A01</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Facteur risque</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Risk factor</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Factor riesgo</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Insuffisance cardiaque</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Heart failure</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Insuficiencia cardíaca</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Traitement</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Treatment</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Tratamiento</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Dopamine agonist</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Maladie de Parkinson</s0><s2>NM</s2><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Parkinson disease</s0><s2>NM</s2><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s2>NM</s2><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Human</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Toxicité</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Toxicity</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Toxicidad</s0><s5>07</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Médicament</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Drug</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Medicamento</s0><s5>08</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Cardiovascular disease</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0><s5>09</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Pharmacovigilance</s0><s5>10</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Pharmacovigilance</s0><s5>10</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Farmacovigilancia</s0><s5>10</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Pramipexole</s0><s2>NK</s2><s2>FR</s2><s5>11</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Pramipexole</s0><s2>NK</s2><s2>FR</s2><s5>11</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Pramipexol</s0><s2>NK</s2><s2>FR</s2><s5>11</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Article synthèse</s0><s5>12</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Review</s0><s5>12</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Artículo síntesis</s0><s5>12</s5></fC03><fC03 i1="13" i2="X" l="FRE"><s0>Revue bibliographique</s0><s5>13</s5></fC03><fC03 i1="13" i2="X" l="ENG"><s0>Bibliographic review</s0><s5>13</s5></fC03><fC03 i1="13" i2="X" l="SPA"><s0>Revista bibliográfica</s0><s5>13</s5></fC03><fC03 i1="14" i2="X" l="FRE"><s0>Antiparkinsonien</s0><s5>23</s5></fC03><fC03 i1="14" i2="X" l="ENG"><s0>Antiparkinson agent</s0><s5>23</s5></fC03><fC03 i1="14" i2="X" l="SPA"><s0>Antiparkinsoniano</s0><s5>23</s5></fC03><fC03 i1="15" i2="X" l="FRE"><s0>Neuroprotecteur</s0><s5>24</s5></fC03><fC03 i1="15" i2="X" l="ENG"><s0>Neuroprotective agent</s0><s5>24</s5></fC03><fC03 i1="15" i2="X" l="SPA"><s0>Neuroprotector</s0><s5>24</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Cardiopathie</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Heart disease</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Cardiopatía</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>41</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0><s5>42</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>42</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>42</s5></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Agoniste</s0><s5>43</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Agonist</s0><s5>43</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Agonista</s0><s5>43</s5></fC07><fC07 i1="08" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0><s5>44</s5></fC07><fC07 i1="08" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0><s5>44</s5></fC07><fC07 i1="08" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0><s5>44</s5></fC07><fN21><s1>132</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Canada</li><li>France</li></country><region><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li></region><settlement><li>Toulouse</li></settlement></list><tree><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name></region><name sortKey="Lapeyre Mestre, Marise" sort="Lapeyre Mestre, Marise" uniqKey="Lapeyre Mestre M" first="Marise" last="Lapeyre-Mestre">Marise Lapeyre-Mestre</name><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><name sortKey="Rey, Maria Ver Nica" sort="Rey, Maria Ver Nica" uniqKey="Rey M" first="María Ver Nica" last="Rey">María Ver Nica Rey</name></country><country name="Canada"><noRegion><name sortKey="Crispo, James" sort="Crispo, James" uniqKey="Crispo J" first="James" last="Crispo">James Crispo</name></noRegion><name sortKey="Krewski, Daniel" sort="Krewski, Daniel" uniqKey="Krewski D" first="Daniel" last="Krewski">Daniel Krewski</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000006 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000006 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:14-0095204
|texte= Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients
}}
| This area was generated with Dilib version V0.6.29. |  |